

MIXiii Health-Tech.IL – OIS Preliminary Program – November 8, 2023



Time	Function										
11:30-11:35	Welcome Remarks <i>Daphne Haim-Langford</i> , PhD, Chairperson, Founder & CEO, Tarsier Pharma										
11:35-11:50	Year in Review <i>Nahum Ferera</i> , CEO and Co-Founder, EyeYon Medical										
11:50-12:15	Keynote Speaker <i>Jason Menzo</i> , Chief Executive Officer, Fighting Blindness Foundation										
12:15-13:00	Company Presentations: Pre-Clinical Stage Moderator: <i>Gilad Litvin</i> , Founder, Chairman, Chief Medical Officer, CorNeat Vision <table border="1" data-bbox="338 732 1056 1024"> <tbody> <tr> <td>12:15</td> <td>OPHTIMED</td> </tr> <tr> <td>12:22</td> <td>BLINK ENERGY</td> </tr> <tr> <td>12:29</td> <td>SUPRA MEDICAL</td> </tr> <tr> <td>12:36</td> <td>OPHRX</td> </tr> <tr> <td>12:43</td> <td>PRECISE BIO</td> </tr> </tbody> </table>	12:15	OPHTIMED	12:22	BLINK ENERGY	12:29	SUPRA MEDICAL	12:36	OPHRX	12:43	PRECISE BIO
12:15	OPHTIMED										
12:22	BLINK ENERGY										
12:29	SUPRA MEDICAL										
12:36	OPHRX										
12:43	PRECISE BIO										
13:00-13:30	Panel Discussion: Pre-Launch Moderator: <i>Daphne Haim-Langford</i> , PhD, Chairperson, Founder & CEO, Tarsier Pharma Panelists: <i>George Megrath, MD</i> , Chief Executive Officer & Board Member, Lexitas <i>Nahum Ferera</i> , CEO and Co-Founder, EyeYon Medical A Moment Before Launch, Moved from The Post Launch Session to Balance <i>Moshe Vardi</i> , Vice President, Global Medicine Team Lead, Alexion Pharmaceuticals Inc. <i>Rami Skaliter</i> , PhD, CEO CellCure Neurosciences <i>Dr. Clair M. Gelfman</i> , Chief Scientific Officer, Fighting Blindness Foundation										

1 *Preliminary program (subject to changes – 08.10.2023)

MIXiii Health-Tech.IL – OIS Preliminary Program – November 8, 2023



13:30-14:30	Lunch														
14:30-15:15	<p>Company Presentations: Clinical Stage Moderator: Dana Rabinovitch, Co-Founder and CEO, OphtiMedRx</p> <table border="1" data-bbox="338 496 999 971"> <tr> <td>14:30</td> <td>DIAGNOSTEAR</td> </tr> <tr> <td>14:36</td> <td>NOVASIGHT</td> </tr> <tr> <td>14:42</td> <td>TARSIER PHARMA</td> </tr> <tr> <td>14:48</td> <td>EVERADS THERAPY</td> </tr> <tr> <td>14:54</td> <td>CORNEAT VISION</td> </tr> <tr> <td>15:00</td> <td>CELLCURE NEUROSCIENCES</td> </tr> <tr> <td>15:06</td> <td>EYEYON MEDICAL – ENDOART</td> </tr> </table>	14:30	DIAGNOSTEAR	14:36	NOVASIGHT	14:42	TARSIER PHARMA	14:48	EVERADS THERAPY	14:54	CORNEAT VISION	15:00	CELLCURE NEUROSCIENCES	15:06	EYEYON MEDICAL – ENDOART
14:30	DIAGNOSTEAR														
14:36	NOVASIGHT														
14:42	TARSIER PHARMA														
14:48	EVERADS THERAPY														
14:54	CORNEAT VISION														
15:00	CELLCURE NEUROSCIENCES														
15:06	EYEYON MEDICAL – ENDOART														
15:15-15:30	<i>Itay Mayer</i> , VP, Managing Director Vision, Lumenis														
15:30-15:45	TBD														

2 *Preliminary program (subject to changes – 08.10.2023)

MIXiii Health-Tech.IL – OIS Preliminary Program – November 8, 2023



<p>15:45-16:15</p>	<p>Panel Discussion: Post-launch Moderator: <i>Prof. Anat Loewenstein, MD, MHA</i>, Chair, Department of Ophthalmology, Tel Aviv Medical Center Panelists: <i>Gianluca Rossetti</i>, Director of Strategic Planning and Business Development at Dompé farmaceutici and member of Engitix’s Board of Directors <i>Daria Lemann-Blumental</i>, CEO, BELKIN Vision <i>Nir Israeli</i>, CEO, Sanoculis <i>Itay Mayer</i>, VP, Managing Director Vision, Lumenis <i>Yoram Gonen</i>, CEO, Hanita Lenses</p>														
<p>16:15-17:00</p>	<p>Company Presentations: Post Approval Stage Moderator: <i>Barak Azmon, MD</i>, Co-Founder & CEO, Notal Vision</p> <table border="1" data-bbox="338 829 999 1284"> <tr> <td>16:15</td> <td>SANOCULIS</td> </tr> <tr> <td>16:21</td> <td>MIKAJAKI, SA</td> </tr> <tr> <td>16:27</td> <td>PERIPHEREX</td> </tr> <tr> <td>16:39</td> <td>BELKIN VISION</td> </tr> <tr> <td>16:45</td> <td>EYEYON – HYPER CL</td> </tr> <tr> <td>16:51</td> <td>ADOM</td> </tr> <tr> <td>16:57</td> <td>TBD</td> </tr> </table>	16:15	SANOCULIS	16:21	MIKAJAKI, SA	16:27	PERIPHEREX	16:39	BELKIN VISION	16:45	EYEYON – HYPER CL	16:51	ADOM	16:57	TBD
16:15	SANOCULIS														
16:21	MIKAJAKI, SA														
16:27	PERIPHEREX														
16:39	BELKIN VISION														
16:45	EYEYON – HYPER CL														
16:51	ADOM														
16:57	TBD														
<p>17:00-17:15</p>	<p><i>Raghuram Selvaraju, PhD., M.B.A.</i>, Managing Director, Senior Healthcare Equity Research Analyst, H.C. Wainwright & Co., LLC</p>														

3 *Preliminary program (subject to changes – 08.10.2023)

MIXiii Health-Tech.IL – OIS Preliminary Program – November 8, 2023



17:15-17:45

Panel Discussion: Investors

Moderator: *Daria Lemann-Blumental*, CEO, BELKIN Vision

Panelists:

Michal Geva, Co-Founder and Managing Partner, Triventures

Limin Wang, PhD, Regional General Manager, Rimonci Capital

Dr. Sean Ianchulev, MD, MPH, Chairman and Founder, Iantrek, Inc., Managing Partner, PME Ventures, Professor of Ophthalmology & Director of Technology and Innovations, New York Eye and Ear of Mount Sinai

Yaacov Michlin, CEO, BioLight Life Sciences Ltd and Chairman of MIXIII Health-Tech.IL

Assaf Barnea, CEO, Sanara Ventures

4 *Preliminary program (subject to changes – 08.10.2023)

MIXiii Health-Tech.IL
Organized by IATI

iAti Israel
Advanced
Technology
Industries